High Plasma Erythropoietin Predicts Incident Fractures in Elderly Men with Normal Renal Function: The MrOS Sweden Cohort

Preclinical studies on the role of erythropoietin (EPO) in bone metabolism are contradictory. Regeneration models indicate an anabolic effect on bone healing, whereas models on physiologic bone remodeling indicate a catabolic effect on bone mass. No human studies on EPO and fracture risk are available. It is known that fibroblast growth factor 23 (FGF23) affects bone mineralization and that serum concentration of FGF23 is higher in men with decreased estimated glomerular filtration rate (eGFR). Recently, a direct association between EPO and FGF23 has been shown. We have explored the potential association between EPO and bone mineral density (BMD), fracture risk, and FGF23 in humans. Plasma levels of EPO were analyzed in 999 men (aged 69 to 81 years), participating in the Gothenburg part of the population‐based Osteoporotic Fractures in Men (MrOS) study, MrOS Sweden. The mean ± SD EPO was 11.5 ± 9.0 IU/L. Results were stratified by eGFR 60 mL/min. For men with eGFR ≥60 mL/min (n = 728), EPO was associated with age (r = 0.13, p < 0.001), total hip BMD (r = 0.14, p < 0.001), intact (i)FGF23 (r = 0.11, p = 0.004), and osteocalcin (r = −0.09, p = 0.022). The association between total hip BMD and EPO was independent of age, body mass index (BMI), iFGF23, and hemoglobin (beta = 0.019, p < 0.001). During the 10‐year follow‐up, 164 men had an X‐ray–verified fracture, including 117 major osteoporotic fractures (MOF), 39 hip fractures, and 64 vertebral fractures. High EPO was associated with higher risk for incident fractures (hazard ratio [HR] = 1.43 per tertile EPO, 95% confidence interval [CI] 1.35–1.63), MOF (HR = 1.40 per tertile EPO, 95% CI 1.08–1.82), and vertebral fractures (HR = 1.42 per tertile EPO, 95% CI 1.00–2.01) in a fully adjusted Cox regression model. In men with eGFR<60 mL/min, no association was found between EPO and BMD or fracture risk. We here demonstrate that high levels of EPO are associated with increased fracture risk and increased BMD in elderly men with normal renal function. © 2019 American Society for Bone and Mineral Research.

[1]  E. Rankin,et al.  Erythropoiesis, EPO, macrophages, and bone. , 2019, Bone.

[2]  T. Ganz,et al.  Effects of erythropoietin on fibroblast growth factor 23 in mice and humans. , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  M. Gassmann,et al.  Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men , 2018, Pflügers Archiv - European Journal of Physiology.

[4]  J. Pike,et al.  A Novel Distal Enhancer Mediates Inflammation‐, PTH‐, and Early Onset Murine Kidney Disease‐Induced Expression of the Mouse Fgf23 Gene , 2017, JBMR plus.

[5]  D. Leaf,et al.  Acute blood loss stimulates fibroblast growth factor 23 production. , 2018, American journal of physiology. Renal physiology.

[6]  M. Ivan,et al.  Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow , 2017, Haematologica.

[7]  Thilo Krüger,et al.  FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase , 2017, PloS one.

[8]  S. Cummings,et al.  Older Men With Anemia Have Increased Fracture Risk Independent of Bone Mineral Density , 2017, The Journal of clinical endocrinology and metabolism.

[9]  D. Mellström,et al.  Low serum iron is associated with high serum intact FGF23 in elderly men: The Swedish MrOS study. , 2017, Bone.

[10]  S. Komarova,et al.  Bone Health in Patients With Hematopoietic Disorders of Bone Marrow Origin: Systematic Review and Meta‐ Analysis , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  A. Pappas,et al.  Endogenous Erythropoietin. , 2017, Vitamins and hormones.

[12]  Y. Gabet,et al.  Erythropoietin in bone – Controversies and consensus , 2017, Cytokine.

[13]  M. Mittelman,et al.  Erythropoietin treatment in murine multiple myeloma: immune gain and bone loss , 2016, Scientific Reports.

[14]  J. Cauley,et al.  Associations of FGF23 With Change in Bone Mineral Density and Fracture Risk in Older Individuals , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  S. Rivella,et al.  Polycythemia is associated with bone loss and reduced osteoblast activity in mice , 2016, Osteoporosis International.

[16]  P. van der Harst,et al.  Erythropoietin in the General Population: Reference Ranges and Clinical, Biochemical and Genetic Correlates , 2015, PloS one.

[17]  M. Gassmann,et al.  Erythropoietin directly stimulates osteoclast precursors and induces bone loss , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  J. Rölfing The effect of erythropoietin on bone , 2014, Acta orthopaedica. Supplementum.

[19]  D. Mellström,et al.  High-Sensitivity CRP Is an Independent Risk Factor for All Fractures and Vertebral Fractures in Elderly Men: The MrOS Sweden Study , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  J. Cauley,et al.  Association of serum fibroblast growth factor 23 (FGF23) and incident fractures in older men: The Osteoporotic Fractures in Men (MrOS) study , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  B. Kestenbaum,et al.  Fibroblast growth factor 23, bone mineral density, and risk of hip fracture among older adults: the cardiovascular health study. , 2013, The Journal of clinical endocrinology and metabolism.

[22]  A. Nemati,et al.  Local Erythropoietin Injection in Tibiofibular Fracture Healing , 2012, Trauma monthly.

[23]  S. Elliott,et al.  The effect of erythropoietin on normal and neoplastic cells , 2012, Biologics : targets & therapy.

[24]  J. Kanis,et al.  High serum adiponectin predicts incident fractures in elderly men: Osteoporotic fractures in men (MrOS) Sweden , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[25]  E. Rankin,et al.  The HIF Signaling Pathway in Osteoblasts Directly Modulates Erythropoiesis through the Production of EPO , 2012, Cell.

[26]  Y. Shiozawa,et al.  Erythropoietin mediated bone formation is regulated by mTOR signaling , 2012, Journal of cellular biochemistry.

[27]  N. Lane,et al.  Effects of inflammation on bone: an update , 2011, Current opinion in rheumatology.

[28]  Huiliang Xie,et al.  Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. , 2011, Kidney international.

[29]  T. Martin,et al.  Erythropoietin couples erythropoiesis, B-lymphopoiesis, and bone homeostasis within the bone marrow microenvironment. , 2011, Blood.

[30]  D. Mellström,et al.  Serum fibroblast growth factor‐23 (FGF‐23) and fracture risk in elderly men , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  L. Ferrucci,et al.  Effect of erythropoietin levels on mortality in old age: the Leiden 85-plus Study , 2010, Canadian Medical Association Journal.

[32]  M. Aickin,et al.  The Relationship Between Incidence of Fractures and Anemia in Older Multiethnic Women , 2010, Journal of the American Geriatrics Society.

[33]  Max Gassmann,et al.  Macrophages as novel target cells for erythropoietin , 2010, Haematologica.

[34]  K. Pienta,et al.  Erythropoietin Couples Hematopoiesis with Bone Formation , 2010, PloS one.

[35]  M. Løchen,et al.  Anemia and the risk of non-vertebral fractures: the Tromsø Study , 2010, Osteoporosis International.

[36]  R. Pereira,et al.  Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. , 2009, Bone.

[37]  D. Mellström,et al.  Plasma Osteocalcin Is Inversely Related to Fat Mass and Plasma Glucose in Elderly Swedish Men , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[38]  I. Holm,et al.  Bone Disease in Thalassemia: A Frequent and Still Unresolved Problem , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[39]  D. Mellström,et al.  Relation between fibroblast growth factor-23, body weight and bone mineral density in elderly men , 2009, Osteoporosis International.

[40]  R. Bellevue,et al.  Bone mass density in adults with sickle cell disease , 2007, British journal of haematology.

[41]  S. Ljungman,et al.  Glomerular filtration rate as measured by serum cystatin C is an important determinant of plasma homocysteine and serum methylmalonic acid in the elderly , 2007, Journal of internal medicine.

[42]  P. Vestergaard,et al.  Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis , 2007, Osteoporosis International.

[43]  O. Johnell,et al.  Free Testosterone is an Independent Predictor of BMD and Prevalent Fractures in Elderly Men: MrOS Sweden , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[44]  S. Bandinelli,et al.  Proinflammatory state and circulating erythropoietin in persons with and without anemia. , 2005, The American journal of medicine.

[45]  G. Keren,et al.  Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. , 2005, Archives of internal medicine.

[46]  R. Taichman Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. , 2005, Blood.

[47]  S. Bandinelli,et al.  Bone density and hemoglobin levels in older persons: results from the InCHIANTI study , 2005, Osteoporosis International.

[48]  Tsuneo Takenaka,et al.  Skeletal effects of erythropoietin in hemodialysis patients , 2004, International Urology and Nephrology.

[49]  Y. Takeuchi,et al.  Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. , 2002, The Journal of clinical endocrinology and metabolism.

[50]  R. Taichman,et al.  Human osteoblasts support human hematopoietic progenitor cells in vitro bone marrow cultures. , 1996, Blood.

[51]  G. Condorelli,et al.  Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. , 1994, The American journal of cardiology.

[52]  W. Jelkmann,et al.  Biology of erythropoietin. , 1994, The Clinical investigator.